Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Quadruplet induction therapy as a new standard of care in multiple myeloma

Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, comments on the tolerability and efficacy of quadruplet induction regimens in transplant-eligible and transplant-ineligible patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.